- Lexaria is making progress with research on its DehydraTECH drug delivery technology
- Advanced 2nd-generation DehydraTECH 2.0 formulations utilized in ongoing hypertension studies
- The company intends to monetize its technology for commercial use
- Its quest for commercial success also follows its move to delist from the Canada Securities Exchange (“CSE”) to focus on the Nasdaq listing
Lexaria Bioscience (NASDAQ: LEXX) continues to innovate with its DehydraTECH(TM) drug-delivery technology. It is constantly collaborating with research institutions and businesses to identify other new ways to improve its technology. So far, advanced DehydraTECH 2.0 formulations are already being used by the company in ongoing human studies. The technology is already being monetized through commercial use (https://ibn.fm/95zra).
As part of its quest for growth and success, Lexaria marked its final trading day on the Canadian Securities Exchange (“CSE”) on Wednesday, July 7, 2021 (https://ibn.fm/a9N8S). The move saw the company consolidate the trading of its shares solely on the Nasdaq. Since it was listed back in January 2021, a substantial fraction of its shareholders moved onto this exchange. To them, it offered more liquidity than ever before, and to Lexaria, it presented an opportunity to realize savings in fees and managerial time.
The company’s management intends to direct the cost savings resulting from this move to its applied research and development programs which would further advance the company’s business. Just earlier this year, Lexaria’s HYPER-A21-1 study resulted in the inclusion of three new DehydraTECH 2.0 formulation variations that would enable cannabidiol (“CBD”) delivery performance enhancements as well as pharmacokinetic optimization (https://ibn.fm/g2VGO). With more funding for such research, Lexaria is well-positioned to achieve even better results and better outcomes for its drug-delivery goals.
Lexaria is recognized as a global innovator in drug delivery platforms. Its proprietary technology, DehydraTECH, improves how active pharmaceutical ingredients (“APIs”) are absorbed into the bloodstream through oral ingestion methods, and the effectiveness of fat-soluble active molecules. With DehydraTECH, Lexaria pushes for fast-acting, less expensive and more effective oral drug delivery that has so far been scrutinized in vitro, vivo and human clinical testing. Its revenue model is mainly comprised of licensing its DehydraTECH to various enterprises around the world, offering consumers the best possible performance across various ingestible product formats. So far, the technology is applicable for different needs that include nicotine-related oral absorption, cannabis-related absorption, antivirals and more.
Currently, Lexaria is working on additional DehydraTECH 2.0 formulations in its HYPER-A21-2 study and other R&D programs. It further plans to carry out advanced research that seeks to evaluate the impacts on real-time blood pressure in animals using specific formulations pursuant of these studies.
Every single move for the company is geared towards levering its technology for hoped-for global commercial use and, so far, everything seems to be on track.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
